AMOLYT PHARMA
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.
AMOLYT PHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics Wellness
Founded:
2007-01-01
Address:
Écully, Rhone-Alpes, France
Country:
France
Website Url:
http://www.amolytpharma.com
Total Employee:
11+
Status:
Active
Contact:
33 4 72 18 94 28
Email Addresses:
[email protected]
Total Funding:
172.65 M USD
Technology used in webpage:
Google Analytics Google Tag Manager WordPress Nginx PHP Typekit Elementor Matomo Astra
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
DVMO
DVMO specializes in the care and therapy of patients with chronic and traumatic wounds.
Forendo Pharma
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
The ophthalmologist
The ophthalmologist is an eye clinic for the treatment of medical and surgical eye disease.
Current Advisors List
Current Employees Featured
Founder
Investors List
Mass General Brigham Ventures
Mass General Brigham Ventures investment in Series B - Amolyt Pharma
Novo Ventures
Novo Ventures investment in Series B - Amolyt Pharma
Pontifax
Pontifax investment in Series B - Amolyt Pharma
OrbiMed
OrbiMed investment in Series B - Amolyt Pharma
Eurazeo
Eurazeo investment in Series B - Amolyt Pharma
Kurma Partners
Kurma Partners investment in Series B - Amolyt Pharma
Sham Innovation Santé
Sham Innovation Santé investment in Series B - Amolyt Pharma
ATEM Capital Fund LP
ATEM Capital Fund LP investment in Series B - Amolyt Pharma
Credit Agricole Entreprises
Credit Agricole Entreprises investment in Series B - Amolyt Pharma
Life Sciences Partners
Life Sciences Partners investment in Series B - Amolyt Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-29 | Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.amolytpharma.com Semrush global rank: 3.64 M Semrush visits lastest month: 3.9 K
- Host name: amolytpharma.wpmudev.host
- IP address: 199.247.18.116
- Location: Frankfurt am Main Germany
- Latitude: 50.1103
- Longitude: 8.7147
- Timezone: Europe/Berlin
- Postal: 60314
